Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • Clinical Oncology
      • Immuno-oncology
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • Clinical Oncology
      • Immuno-oncology
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
News in Brief

HHS Expands Rules for Clinical Trial Reporting

DOI: 10.1158/2159-8290.CD-NB2016-132 Published December 2016
  • Article
  • Info & Metrics
  • PDF
Loading

The federal government has adopted new policies to clarify and expand the reporting requirements for clinical trials and to make the data available more quickly to researchers and the public. Noting that previous rules were ambiguous and often ignored, federal officials vowed to enforce the new requirements and pull public funding from studies that do not comply.

The new rules from the U.S. Department of Health and Human Services (HHS) and the NIH, which take effect on January 18, 2017, outline the requirements for registering and submitting summary results to ClinicalTrials.gov for all publicly funded trials. Key changes include mandatory registration of trials that test experimental and early-stage therapies, and posting results for trials of unapproved drugs.

The rules also clarify the definition of an Applicable Clinical Trial and provide a checklist of mandatory data requirements for registration, such as information about the design and outcome measures and recruitment eligibility criteria. In addition, more information must be submitted on completed trials, including demographic characteristics of participants and details of any adverse events that affect more than 5% of patients. The key points are described in The New England Journal of Medicine (N Engl J Med 2016 Sept 16 [Epub ahead of print]).

“Sharing results is society's responsibility toward the volunteers who agree to participate in trials,” said NIH Director Francis Collins, MD, PhD, at a press conference, “but we as a community have had a disappointing track record at making those results available.”

Under the existing rule, researchers must submit results of federally funded research within a year of completing a trial, but that often doesn't happen. Collins cited a recent study showing that among trials conducted at 51 U.S. academic medical centers, 43% had not published their results within 2 years of completion (BMJ 2016;352:i637). A separate review of 400 studies found that 30% had not reported results within 4 years (PLoS ONE 2014;9:e101826).

Officials anticipate a flood of new trial registrations as a result of the ruling, said Collins, and the FDA is making plans to strengthen enforcement.

Sponsors of publicly funded studies that do not comply will face stiff penalties, including fines and withdrawal of funding for future trials, noted FDA Commissioner Robert Califf, MD, during the news conference. The FDA plans to fold compliance and enforcement activities into its existing Bioresearch Monitoring program, through which it collects clinical trial information during site inspections.

“We are already at a number of these trial sites on a routine basis,” Califf noted. “Once people realize how serious this is, we don't think that we will have a lot of problems with compliance. No one wants to be on the “wall of shame' for failing to report their results.” –Janet Colwell

Notes

For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2016 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 6 (12)
December 2016
Volume 6, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
HHS Expands Rules for Clinical Trial Reporting
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
HHS Expands Rules for Clinical Trial Reporting
Cancer Discov December 1 2016 (6) (12) 1296; DOI: 10.1158/2159-8290.CD-NB2016-132

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
HHS Expands Rules for Clinical Trial Reporting
Cancer Discov December 1 2016 (6) (12) 1296; DOI: 10.1158/2159-8290.CD-NB2016-132
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Bempegaldesleukin Boosts Responses in Melanoma
  • Siglec-15: An Attractive Immunotherapy Target
  • MCLA-128 Fights NRG1 Fusion–Positive Cancers
Show more News in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement